Ionis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	966.96	705.14	787.65	587.37	810.46	729.26
Revenue Growth (YoY)	20.41%	-10.47%	34.10%	-27.53%	11.13%	-35.04%
Cost of Revenue	893.25	912.75	908.76	847.26	654.3	11.95
Gross Profit	73.71	-207.61	-121.11	-259.9	156.16	717.32
Selling, General & Admin	351.76	267.47	212.62	150.3	186.35	354.32
Research & Development	-	-	-	-	-	535.08
Operating Expenses	351.76	267.47	212.62	150.3	186.35	889.4
Operating Income	-278.05	-475.08	-333.73	-410.19	-30.19	-172.08
Interest Expense	-90.72	-90.45	-81.46	-8.12	-9.35	-9.51
Interest & Investment Income	101.95	107.02	89.04	25.33	10.04	30.56
Other Non Operating Income (Expenses)	1.24	1.34	0.87	-7.27	-1.13	-0.06
EBT Excluding Unusual Items	-265.58	-457.17	-325.28	-400.26	-30.62	-151.09
Gain (Loss) on Sale of Investments	6.86	-2.89	-1.91	-7.33	10.1	16.54
Gain (Loss) on Sale of Assets	-0.01	-0.01	-0.16	149.6	-	-
Other Unusual Items	-	-	-6.61	-	-8.63	-
Pretax Income	-258.72	-460.07	-333.97	-257.99	-29.15	-134.55
Income Tax Expense	-2.38	-6.17	32.32	11.74	-0.55	345.19
Earnings From Continuing Operations	-256.34	-453.9	-366.29	-269.72	-28.6	-479.74
Minority Interest in Earnings	-	-	-	-	-	35.48
Net Income	-256.34	-453.9	-366.29	-269.72	-28.6	-444.26
Net Income to Common	-256.34	-453.9	-366.29	-269.72	-28.6	-444.26
Shares Outstanding (Basic)	159	150	143	142	141	140
Shares Outstanding (Diluted)	159	150	143	142	141	140
Shares Change (YoY)	8.89%	4.42%	0.95%	0.59%	1.01%	-8.85%
EPS (Basic)	-1.61	-3.04	-2.56	-1.90	-0.20	-3.18
EPS (Diluted)	-1.61	-3.04	-2.56	-1.90	-0.20	-3.18
Free Cash Flow	-302.66	-546.23	-331.32	-290.09	18.84	0.77
Free Cash Flow Per Share	-1.91	-3.65	-2.31	-2.04	0.13	0.01
Gross Margin	7.62%	-29.44%	-15.38%	-44.25%	19.27%	98.36%
Operating Margin	-28.75%	-67.37%	-42.37%	-69.84%	-3.72%	-23.60%
Profit Margin	-26.51%	-64.37%	-46.50%	-45.92%	-3.53%	-60.92%
Free Cash Flow Margin	-31.30%	-77.46%	-42.06%	-49.39%	2.33%	0.11%
EBITDA	-266.8	-463.13	-320.88	-393.45	-12.35	-156.65
EBITDA Margin	-27.59%	-65.68%	-40.74%	-66.98%	-1.52%	-21.48%
D&A For EBITDA	11.25	11.95	12.85	16.74	17.84	15.43
EBIT	-278.05	-475.08	-333.73	-410.19	-30.19	-172.08
EBIT Margin	-28.75%	-67.37%	-42.37%	-69.84%	-3.72%	-23.60%
Revenue as Reported	966.96	705.14	787.65	587.37	810.46	729.26

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.